Jakub Radocha

14PUBLICATIONS
82CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Autoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jun 12, 2026
Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

|Aug 05, 2025
Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.

María-Victoria Mateos, Suzanne Trudel, Hang Quach

|Oct 31, 2022
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.

Tomas Jelinek, Renata Bezdekova, David Zihala

|Oct 27, 2022
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy.

Jiri Minarik, Jakub Radocha, Alexandra Jungova

|Jul 11, 2021
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.

Tomas Jelinek, Tereza Sevcikova, David Zihala

|Apr 03, 2021
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma.

Jakub Radocha, Niels W C J van de Donk, Katja Weisel

Pageof 3

Frequent Collaborators

5 joint publications

Tomas Jelinek

4 joint publications

Roman Hájek

3 joint publications

Martin Stork

3 joint publications

Jiri Minarik